Introduction
The acquisition of immune responsiveness is mediated through the assembly, expression and function of antigen receptors at the cell surface 1 . In T lymphocytes, the antigen T cell receptor (TCR) is a multi-subunit complex comprising clonotypic, disulfide-linked α and β antigen recognition chains devoid of signalling motifs associated with the invariant chain subunits CD3γ, δ and ε, and TCRζ 2 . These invariant chains assemble in the mature TCR/CD3 complex as noncovalently linked CD3γε and CD3δε heterodimers and disulfide-linked TCRζ−ζ homodimers and transmit signals inside the cell following TCR ligation-induced tyrosine phosphorylation of immune-receptor tyrosine-based activation motifs contained within their extended intracytoplasmic tails [3] [4] [5] . These phosphotyrosine motifs form docking sites for Syk family tyrosine kinases, such as ζ-associated protein of 70 kDa (ZAP-70), which in turn couple the antigen receptor complex to transmembrane adaptor proteins and downstream signalling pathways 6 .
The TCRζ subunit differs in its genetic organisation, chromosomal localization and domain structure from the CD3γ, δ and ε invariant chains. Thus, in CD4 + and CD8 + T cells the 16kDa
TCRζ chain subserves a unique role in TCR/CD3 complex assembly by associating with newly synthesized hexameric αβγεδε complexes resulting in the transport and expression of mature αβγεδεζ 2 complexes to the cell surface 7 . Furthermore, metabolic labelling and pulse chase experiments have demonstrated that de novo synthesis of TCRζ is rate-limiting thereby regulating the amount of TCR/CD3 complex expressed at the cell surface 8, 9 . In NK cells, the TCRζ chain may form homodimers or heterodimers with the FcεR common γ chain signalling subunit, which in turn may form signalling complexes with several activating receptors, including NK cell protein 46 (NKp46), NKp30 and the low affinity IgG receptor FcγRIII (CD16) 10, 11 . In light of these
For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From crucial functions the TCRζ chain could be viewed as a master regulator and sensor of innate as well as adaptive immune responses. It follows from this that aberrations in its expression or function should have profound effects on immune function.
The events leading to the downregulation of TCR/CD3 complex expression upon serial ligation by peptide/MHC complexes are well documented 12 . Less well understood are the molecular mechanisms for the sustained downregulation of TCRζ observed in chronic bacterial, human immunodeficiency virus and mycobacterial infections, autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, and in solid tumour and haematological malignancies (reviewed in 13) . That this phenomenon is associated with so many diverse pathologies has raised the possibility that downregulation of TCRζ may serve to attenuate T cell activation at sites of tissue damage thereby limiting the effects of unbridled T cell reactivity and pathological effector responses 14, 15 . Whilst this model is entirely consistent with a central role for antigen in driving autoimmune inflammatory activity, it implies that chronically activated T cells rendered hyporesponsive to TCR engagement through loss of TCRζ expression should play a less prominent role in the established phase of disease 13, 14 .
To gain further insight into the immunobiology of T cells expressing low levels of TCRζ 
Materials and methods

Healthy donors and patients
Laboratory staff aged between 22 and 45 years of age were enrolled as healthy donors. All patients were recruited from the Hammersmith Hospitals NHS Trust, London, UK. CMV reactive lymphocytes were obtained from HLA-B*0702 positive patients with chronic myeloid leukaemia selected by cytomegalovirus (CMV) seropositivity. Single donor plateletpheresis residues were obtained from the North London Blood Transfusion Service (Colindale, UK). Patients with severe, active seropositive rheumatoid arthritis (RA) meeting the American College of Rheumatology revised classification criteria for RA 16 , and requiring anti-TNF therapy, were recruited to the study. Prior to anti-TNF therapy, all patients were treated with non-steroidal antiinflammatory drugs in addition to methotrexate and sulphasalazine, with or without hydroxychloroquine and low dose prednisolone. Peripheral blood (PB) and synovial fluid (SF) lymphocytes were obtained from patients with RA, psoriatic arthritis or reactive arthritis who attended the clinic with a flare of disease requiring therapeutic arthrocentesis. Synovial mononuclear cell suspensions were prepared from RA synovial tissue obtained at joint replacement surgery as described 17 . Written, informed consent was obtained from all participating donors and patients according to the Declaration of Helsinki, and all protocols were approved by the Riverside Research Ethics Committee, Hammersmith Hospitals NHS Trust.
Human lymphocytes
PB lymphocytes (PBL) from heparinized peripheral venous blood (or mononuclear cells from synovial fluid) were obtained by Ficoll-Hypaque density gradient centrifugation (specific density 1.077 g/ml; Nycomed Pharma, Oslo, Norway) and used immediately for flow cytometric analysis. Where relevant, additional aliquots were prepared and frozen until required. PB monocytes and T cells were purified by elutriation (JE6; Beckman Coulter, Fullerton, CA) in 1% heat-inactivated foetal calf serum (FCS), as described 17 , and purity assessed by flow cytometry. Single cell suspensions of synovial membrane mononuclear cells were prepared as described 17 . Cells were cultured in RPMI-1640 supplemented with 10% heat-inactivated FCS, 2 mM L-glutamine, 100 U/ml penicillin/streptomycin, 50 µM 2-ME, 1 mM sodium pyruvate and 25 mM HEPES (complete medium).
Antibodies and recombinant cytokines
The following antibodies were purchased from BD Biosciences Pharmingen (San Diego, CA): 
Flow cytometry
Cells were stained by standard methods and analysed using an LSR BD FACScan analyzer and CellQuest software (Becton Dickinson). For analysis of TCRζ and intracellular cytokine expression, cells were fixed with 2% formaldehyde and permeabilised in buffer containing 10 µg/ml saponin, according to established protocols 18 . The efficiency of permeabilisation was determined by uptake of trypan blue (always > 99%).
T cell stimulation and effector responses
For proliferation, unfractionated PBL were labelled with 5 µM CFSE (Molecular Probes, Eugene, OR) prior to stimulation in complete medium with plate bound OKT3 (2 µg/ml) with or without soluble anti-CD28 (2 µg/ml). Cells were harvested at the indicated times, stained with specific antibodies to TCRζ (TIA2-PE), together with anti-CD3, -CD4 or -CD8 conjugated to PerCP and analysed by flow cytometry. CMV reactive PBLs were stimulated with specific pp65 CMV peptide (amino acid sequence: TPRVTGGGAM, from Proimmune, Oxford, UK) in the presence of 50 U/ml IL-2 and 10 ng/ml IL-7 for up to 8 days prior to staining with anti-TCRζ (6B10.2-FITC),
HLA-B7-tetramer-PE (Proimmune) and anti-CD8-APC and analysis by flow cytometry. Cytokine activated T cells were generated from elutriated T cells over 8 days using IL-2 (25 ng/ml), TNFα (25 ng/ml) and IL-6 (100 ng/ml) as described 17 . Cytokine expression was determined by staining fixed and permeabilised PBL with directly conjugated anti-cytokine antibodies (all from BD Pharmingen), after stimulation for 6 hr at 37°C with 20 ng/ml phorbal myristate acetate (PMA) and 200 ng/ml ionomycin (both from Sigma). Golgistop (containing monensin, from BD Pharmingen) was added for the last hour of stimulation. Specificity of staining was confirmed using isotype 
Assessment of clinical response
Patients with active RA requiring anti-TNF treatment as part of their standard care were identified according to national guidelines. All patients were treated with intravenous infusions of infliximab (3 mg/kg) at week 0, 2, 6 and 8 weekly thereafter, whilst continuing existing disease modifying drug therapy. At baseline and at the indicated times disease activity and response to therapy was determined using the disease activity score (DAS) which includes the 28 joint count (DAS28) 20 .
At baseline, all patients had DAS28 scores of > 5. Correlations between changes in TCRζ expression and disease activity were determined by linear regression analysis. The limit for statistical significance was set at 0.05. Figure 2C ); note the downward shift in tetramer staining consequent upon downregulation of the TCR complex after stimulation ( Figure 2B and C, right panels A characteristic feature of effector T cells is their capacity to produce cytokines. Current paradigms of T cell differentiation suggest that T cells undergo a complex series of epigenetic events in order to acquire stable transcriptional competence for cytokine gene expression 23 . These events depend upon signals integrated from both the antigen T cell receptor and cytokine receptors which induce the expression and activation of lineage specific transcription factors 24 . We therefore explored whether TCRζ dim T cells that had already engaged antigen in vivo were competent for cytokine gene expression when compared to TCRζ bright cells from the same donor.
To test this, fresh PBL were stimulated in vitro for 6 hr with phorbol ester and calcium ionophore. Figure 3A and B) . By contrast, the dominant IL-10 producing cell subset was found to reside within the TCRζ bright subset ( Figure 3C ), indicating that cytokine expression in general was not confined to the TCRζ dim subset. A similar trend was seen for IL-4, but levels of expression were too low for a meaningful statistical analysis.
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The results described thus far indicated that circulating TCRζ dim T cells were enriched for cells that had previously engaged antigen, and which were primed for cytokine production. However, the proliferative responses of T cells to TCR engagement shown in Figure 2 indicated that the Figure 6A ), and the expression profiles for upper and lower chambers were quite comparable to those we had observed for PB and SF ( Figure 5A ). Figure 6B ). Migration of PBL could be further enhanced by the addition of CXCL-10, CCL5 or CXCL-12 to the lower chamber, chemokines known to be upregulated in RA synovial joints ( Figure 6C ) 29 . Subset analysis revealed enhanced migration of TCRζ bright T cells in the presence of CXCL-12 ( Figure 6D ), while the migratory profiles of TCRζ dim cells were substantially higher and barely augmented in the presence of exogenous chemokine ( Figure 6D ). While such sustained T cell effector responses might usefully serve to sustain immunity to foreign pathogens, they are clearly harmful in autoimmunity.
A direct link between the loss of integrity of signalling from the TCR/CD3 complex and the generation of a repertoire of arthritogenic T cells has recently been reported in SKG mice 39 . PBL acquired from RA patients at baseline and 14 weeks after treatment with anti-TNF were analysed for their capacity to migrate in vitro using the transendothelial migration assay.
Migrating cell subsets were determined by flow cytometry. 
